ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2249 • ACR Convergence 2022

    Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study

    Gabriel Figueroa Parra1, Emily Gilbert2, Maria Valenzuela Almada1, Sebastian Vallejo1, Matthew Neville3, Naomi Patel4, Claire Cook5, Xiaoqing Fu5, Ramla Hagi5, Gregory McDermott6, Michael Dilorio6, Lucy Masto6, Kathleen Vanni6, Emily Kowalski6, Grace Qian6, Zachary Wallace5, Ali Duarte-Garcia1 and Jeffrey Sparks7, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Jacksonville, FL, 3Mayo Clinic, Phoenix, AZ, 4Massachusetts General Hospital, Sale Creek, TN, 5Massachusetts General Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…
  • Abstract Number: 2250 • ACR Convergence 2022

    Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Austin Wheeler1, Yangyuna Yang1, Joshua Baker2, Jill Poole1, Dana Ascherman3, Gail Kerr4, Andreas Reimold5, Gary Kunkel6, Grant Cannon7, Katherine Wysham8, Namrata Singh9, Deana Lazaro10, Paul Monach11, S. Louis Bridges, Jr.12, Ted Mikuls13 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Pittsburgh, Pittsburgh, PA, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5University of Texas Southwestern Medical Center, Dallas, TX, 6University of Utah, Salt Lake City, UT, 7Retired, Salt Lake City, UT, 8VA Puget Sound/University of Washington, Seattle, WA, 9University of Washington, Bellevue, WA, 10VA New York Harbor Healthcare system, Short Hills, NJ, 11VA Boston Healthcare System, Boston, MA, 12Hospital for Special Surgery, New York, NY, 13Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA causing substantial morbidity and mortality. Genetic risk variants, such as the MUC5B rs35705950…
  • Abstract Number: 2244 • ACR Convergence 2022

    Salient Coping Strategies Among Youth with Chronic Musculoskeletal Pain

    Sabrina Gmuca1, Daneka Stryker2, Mackenzie McGill1, Whitney Eriksen3 and Peter F. Cronholm4, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Drexel University College of Medicine, Philadelphia, PA, 3Jefferson Health, Philadelphia, PA, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Youth with chronic musculoskeletal pain (CMP) learn pain-coping strategies and build resilience through cognitive behavioral therapy (CBT). In order to expand therapeutic options for…
  • Abstract Number: 2126 • ACR Convergence 2022

    Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials

    Shawn Kwatra1, Saakshi Khattri2, Ahmad Amin3, Huzefa Photowala4, Ran Liu4, Byron Padilla5, Blair Kaplan4 and Dennis McGonagle6, 1John Hopkins University, Baltimore, MD, 2Mount Sinai Medical Center, New York, NY, 3Northwestern Medicine Dermatology, Chicago, IL, 4AbbVie, Inc., North Chicago, IL, 5AbbVie, Inc., Waukegan, IL, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) is a progressive condition with chronic inflammation and joint destruction impacting quality of life.1 Dactylitis and enthesitis are clinically relevant domains…
  • Abstract Number: 2190 • ACR Convergence 2022

    Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis

    Yen Chen1, Alain Lescoat2, Dinesh Khanna3 and Susan Murphy4, 1University of Michigan, Ann Arbor, MI, 2CHU Rennes - University Rennes 1, Rennes, France, 3Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 4University of Michigan, Grosse Ile, MI

    Background/Purpose: Individuals with systemic sclerosis (SSc) report cognitive problems that worsen symptoms and daily activity performance. Compensatory cognitive strategies (CCS) are commonly taught to help…
  • Abstract Number: 2236 • ACR Convergence 2022

    Association of microRNA-30b Plasma Expression with Fibromyalgia Clinical Features and with Corneal Small Nerve Fiber Pathology

    Laura Aline Martínez Martínez1, Fausto Sánchez Muñoz1, Manuel Ramírez Fernández2, Yaneli Juárez Vicuña1, Mario Peña-Peña1, Carlos Alfonso Guzman Martin1, Itzel Palafox Sosa1 and Manuel Martínez-Lavín1, 1Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 2APEC Hospital de la ceguera, Ciudad de México, Mexico

    Background/Purpose: There is a clear association between fibromyalgia and small fiber neuropathy. Dorsal root ganglia contain the small nerve fiber nuclei. Severe fibromyalgia is associated…
  • Abstract Number: 2030 • ACR Convergence 2022

    Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome

    Jonathan Hubbard1, Kim Campbell1, Kathy Sivils1, Robert Hoffman1, Kim Hung Lo1, Jocelyn Leu1, Sophia Liva1, Qing Zuraw1, Anne Stevens1, Leona Ling2, Keith Karcher3, Sindhu Ramchandren3, Hong Sun3, Hal Scofield4, Daniel Wallace5 and Raphaèle Seror6, 1Janssen Research and Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Cambridge, MA, 3Janssen Research & Development, LLC, Titusville, NJ, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Cedars-Sinai Medical Center, Los Angeles, CA, 6University Hospital Paris-Saclay, Le Kremlin Bicêtre, France

    Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…
  • Abstract Number: 1841 • ACR Convergence 2022

    To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis

    María Paula Álvarez Hernández1, Alfredo Madrid-García2, Alejandro Gómez Gómez3, Lara Borrego Sanz4, Rosalía Méndez Fernández4, Pedro Arriola Villalobos4, Esperanza Pato Cour5, David Díaz Valle4 and Luis Rodriguez-Rodriguez5, 1Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, Madrid, Spain, 3Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, 4Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, 5Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain

    Background/Purpose: Non-infectious uveitides (NIUs) include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed…
  • Abstract Number: 2223 • ACR Convergence 2022

    Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus

    Julius Lindblom1, Daniel Toro-Domínguez2, Elena Carnero-Montoro2, Maria Orietta Borghi3, Jessica Castillo4, Ellen Iacobaeus1, Yvonne Enman5, Chandra Mohan4, Marta Alarcon-Riquelme2, Guillermo Barturen2 and Ioannis Parodis1, 1Karolinska Institutet, Stockholm, Sweden, 2Center for Genomics and Oncological Research (GENYO), Granada, Spain, 3Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, 4University of Houston, Houston, TX, 5Karolinska Institutet, Sundbyberg, Sweden

    Background/Purpose: Involvement of the nervous system is a common but poorly understood manifestation of SLE, termed NPSLE. Although studies have reported varying prevalence estimates (Unterman…
  • Abstract Number: 2247 • ACR Convergence 2022

    Priority Research Topics for Vaccine Uptake Among Adults with Autoimmune Conditions

    Shilpa Venkatachalam1, William Benjamin Nowell2, Shubhasree Banerjee3, Kelly Gavigan4, Laura Stradford2, Jennifer Gordon5, Lisa Emerich6, Hope Sullivan7, Ashira Blazer8, Brittany Banbury9, Vandana Dronadula1, Kimberly Weaver10, Angela Degrassi4, Peter Merkel3, Robert McBurney11, Mike Kappelman10, Jeffrey Curtis12 and Michael George3, 1Global Healthy Living Foundation, New York, NY, 2Global Healthy Living Foundation, Nyack, NY, 3University of Pennsylvania, Philadelphia, PA, 4Global Healthy Living Foundation, Upper Nyack, NY, 5Vasculitis Foundation, Philadelphia, 6iConquerMS, Waltham, MA, 7Inflammatory Bowel Disease (IBD) Partners, Chapel Hill, NC, 8Hospital for Special Surgery, New York, NY, 9NYU Langone, Fort Lee, NJ, 10School of Medicine, University of North Carolina (UNC), Chapel Hill, NC, 11Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, 12University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Compared to the general population, adults living with autoimmune disease are at nearly twice the risk of vaccine-preventable infections, making this a high priority…
  • Abstract Number: 2232 • ACR Convergence 2022

    Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteritis Nodosa Diagnosed Since 2005: Data from 196 Patients

    Julien ROHMER1, ludovic trefond2, Yann Nguyen3, Christian Agard4, Jean Sebastien ALLAIN5, Alice Berezne6, Pierre Charles7, Pascal Cohen8, guillaume gondran9, Matthieu GROH10, Tessa HUSCENOT11, carole lacout12, Estibaliz Lazaro13, Jonathan London14, Francois Maurier15, Arsene Mekinian16, Isabelle Nubourgh17, Rafik MESBAH18, Xavier Puéchal8, Laurent Perard19, Mathieu Puyade20, Gregory Pugnet21, Viviane Queyrel22, Diane Rouzaud23, Arthur Roux24, Cecile-Audrey DUREL19, Loïc Guillevin8 and Benjamin Terrier8, 1APHP, Suresnes, France, 2Chu clermont ferrand, Clermont-Ferrand, France, 3AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, 4Internal medicine, Nantes University Hospital, Nantes, France, 5CHU rennes, Rennes, 6CH Annecy, Annecy, France, 7Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, 8National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 9CHU limoges, Limoges, France, 10Foch Hospital, Suresnes, France, 11APHP, Boulogne, France, 12CHU Angers, Angers, France, 13Bordeaux Hospital University, Bordeaux, France, 14Hôpital Croix-Saint-Simon, Paris, France, 15Hôpitaux privés de Metz, Metz, France, 16AP-HP, Hopital Saint Antoine, Paris, France, 17Ch St Pierre, Brussels, Belgium, 18Boulogne Ch, Boulogne, France, 19CHU Lyon, Lyon, France, 20Centre Hospitalier Universitaire de Poitiers, Poitiers, France, 21CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, 22CHU NIce, Nice, France, 23Bichat, Paris, France, 24MGEN, Paris, France

    Background/Purpose: The etiological landscape of systemic polyarteritis nodosa (PAN) has substantially changed since the onset of hepatitis B virus (HBV) vaccination and the discovery of…
  • Abstract Number: 2200 • ACR Convergence 2022

    Reliability of Medication Information Derived from EHR Data Compared to Insurance Claims: An Analysis of Biologic Medications in RISE and Medicare

    Rahaf Baker1, Jing Li2, Rachael Stovall3, Jeffrey Curtis4, Fenglong Xie5, Jinoos Yazdany6 and Gabriela Schmajuk7, 1Alameda Highland Internal Medicine Residency, Oakland, CA, 2University of California, San Francisco, San Francisco, CA, 3University of California San Francisco, San Francisco, CA, 4University of Alabama at Birmingham, Hoover, AL, 5University of Alabama at Birmingham, Birmingham, AL, 6UCSF, San Francisco, CA, 7UCSF / SFVA, San Francisco, CA

    Background/Purpose: Health services studies increasingly rely on Electronic Health Record (EHR) data to capture medication use. However, the reliability of medication information derived from EHR…
  • Abstract Number: 2139 • ACR Convergence 2022

    Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

    Iain B McInnes1, Philipp Sewerin2, Mohamed Sharaf3, Michela Efficace4, May Shawi5, Michelle Perate6, Miriam Zimmermann7 and Laura Coates8, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Janssen Cilag SpA, Imperia, Italy, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham, PA, 7Janssen Scientific Affairs, LLC, Zug, Switzerland, 8Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
  • Abstract Number: 2043 • ACR Convergence 2022

    What Does Isolated Anti-Ro52 Antibody Positivity Mean in Sjögren’s Syndrome?

    Eléonore Bettacchioli1, Alain Saraux2, Alice Tison3, Divi CORNEC4, Maryvonne Dueymes1, Marta Alarcon-Riquelme5 and Valerie Devauchelle6, 1Immunology and Immunotherapy Laboratory, CHRU Brest, Brest, France, 2CHU Brest, Brest, France, 3Rheumatology Department, CHRU Brest, Brest, France, 4CHRU Brest, Brest, France, 5Center for Genomics and Oncological Research (GENYO), Granada, Spain, 6Université de Bretagne Occidentale, Brest, France

    Background/Purpose: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by a triad of dryness, pain and fatigue in affected patients. Its diagnosis is…
  • Abstract Number: 2038 • ACR Convergence 2022

    Single Cell RNA Sequencing Points to a Role for Fibroblasts Early in Salivary Gland Dysfunction in Primary Sjögren’s Syndrome

    Sarah Pringle1, Fred Spijkervet1, Arjan Vissink2, Hendrika Bootsma1 and Frans Kroese1, 1University Medical Center Groningen, Groningen, Netherlands, 2UMCG, Leek, Netherlands

    Background/Purpose: Salivary gland (SG) dysfunction is commonly associated with the autoimmune disease primary Sjögren's syndrome (pSS). Whilst the more advanced stages of the disease are…
  • « Previous Page
  • 1
  • …
  • 432
  • 433
  • 434
  • 435
  • 436
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology